Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Peter Herhaus, Julia Meissner, Karolin Trautmann-Grill, Horst Müller, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Karolin Behringer

Blood (2023) 142 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2023-189250

Published: 2023

Journal Articles

Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Peter Herhaus, Julia Meissner, Karolin Trautmann-Grill, Horst Müller, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Karolin Behringer

Blood (2023) 142 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2023-188734

Published: 2023

Journal Articles

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann-Grill, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow

Blood (2022) 140 (Supplement 1): 1753–1755.

https://doi.org/10.1182/blood-2022-168846

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

Nora Liebers, Claudius Speer, Louise Benning, Peter-Martin Bruch, Isabelle Kraemer, Julia Meissner, Paul Schnitzler, Hans-Georg Kräusslich, Peter Dreger, Carsten Mueller-Tidow, Isabel Poschke, Sascha Dietrich

Blood (2022) 139 (1): 142–147.

https://doi.org/10.1182/blood.2021013445

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138413

Published: 2020

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Blood (2019) 134 (Supplement_1): 236.

https://doi.org/10.1182/blood-2019-122406

Published: 2019

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, MD, Thomas Luft, MD PhD, Andrea Bondong, Ute Hegenbart, MD, Julia Meissner, MD, Nora Liebers, Michael Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger

Blood (2019) 134 (Supplement_1): 3328.

https://doi.org/10.1182/blood-2019-128352

Published: 2019

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Paul J Bröckelmann, MD, Annette Plütschow, Richard Greil, MD, Josée M Zijlstra, MD PhD, Timothy Illidge, MD PhD, Alexander Fosså, MD PhD, Julia Meissner, MD, Andreas Zimmermann, MD, Stephan Mathas, MD, Felicitas Thol, MD, Michael Fuchs, MD, Andreas Engert, MD, Christian Baues, MD

Blood (2019) 134 (Supplement_1): 1547.

https://doi.org/10.1182/blood-2019-124351

Published: 2019

Journal Articles

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

Georg Hess, Andreas Hüttmann, MD, Julia Meissner, MD, Reinhard Marks, Martin Dreyling, MD PhD, Ulrich Keller, Thomas Ernst, Christiane Pott, Andreas Viardot, MD, Oliver Deuster, Christina van Oordt, Matthias Theobald, Georg Lenz

Blood (2018) 132 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2018-99-116670

Published: 2018

Journal Articles

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Boris Boell, MD, Alexander Fosså, MD PhD, Helen Goergen, Peter Kamper, Sirpa Leppa, MD Prof, Daniel Molin, Julia Meissner, MD, Ellen Ritter, MD, Jacob H. Christensen, Martin Hutchings, MD, Michael Fuchs, Andreas Engert, MD, Carsten Kobe, MD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 926.

https://doi.org/10.1182/blood-2018-99-119363

Published: 2018

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

Journal Articles

Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study

Bastian von Tresckow, Michelle A. Fanale, MD, Kirit M Ardeshna, MA MDFRCP FRCPath, Robert W. Chen, MD, Julia Meissner, MD, Franck Morschhauser, MD PhD, Craig H. Moskowitz, MD, Pier Luigi Zinzani, MD, Hilde Giezek, Arun Balakumaran, MD PhD, Monika Raut, PhD MS, Thao Vo, Pauline Brice, MD

Blood (2017) 130 (Supplement 1): 2169.

https://doi.org/10.1182/blood.V130.Suppl_1.2169.2169

Published: 2017

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Saad Akhtar, MD, Silvia Montoto, MD, Ariane Boumendil, PhD, Luca Castagna, MD, Herve Finel, Tamas Masszi, MD, Pavel Jindra, MD PhD, Damir Nemet, MD PhD, Herrad Baurmann, MD, Yves Beguin, MD PhD, Felicetto Ferrara, Saveria Capria, MD, Ram Malladi, MD PhD, Jose M Moraleda, MD PhD, Gilles Salles, MD PhD, Adrian Bloor, Julia Meissner, MD, Anna Sureda, MD, Peter Dreger, MD

Blood (2016) 128 (22): 514.

https://doi.org/10.1182/blood.V128.22.514.514

Published: 2016

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Mathias Witzens-Harig, MD, Andreas Viardot, Ulrich Keller, Christian Buske, Anne Crombé, Elisabeth Hoenig, Johannes Atta, Johann Schmier, MD, Julia Meissner, MD, Anthony D. Ho, MD, Paul LaRosee, MD, Reinhard Marks, MD, Martin Dreyling, MD PhD, Georg Hess, MD

Blood (2016) 128 (22): 3028.

https://doi.org/10.1182/blood.V128.22.3028.3028

Published: 2016

Journal Articles

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Stefanie Kreissl, MD, Helen Goergen, Bastian von Tresckow, MD, Karolin Behringer, MD, Jana Markova, MD, Andreas Lohri, MD, Julia Meissner, MD, Josée M Zijlstra, MD, Richard Greil, MD, Max S. Topp, MD, Martin Sökler, MD, Hartmut Döhner, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2015) 126 (23): 3941.

https://doi.org/10.1182/blood.V126.23.3941.3941

Published: 2015

Journal Articles

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

Mathias Witzens-Harig, MD, Ulrich Keller, Andreas Viardot, MD, Christian Buske, MD, Anne Crombé, Elisabeth Hoenig, Julia Meissner, MD, Anthony D Ho, MD, Reinhard Marks, Martin H. Dreyling, MD PhD, Georg Hess, MD

Blood (2015) 126 (23): 2727.

https://doi.org/10.1182/blood.V126.23.2727.2727

Published: 2015

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

NARROW

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Quality of Life with Nivolumab and AVD First-Line Treatment in Hodgkin Lymphoma: Patient-Reported Outcomes from the Phase II GHSG Nivahl Trial

Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients

Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma:Â a Phase II Trial (GOAL)

B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Patient-Reported Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab Monotherapy, Results of a Phase 2 Study

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only